PR020 - April 2009
Lipoxen plc and Cambridge Biostability Ltd
Positive Data for Revolutionary Influenza Vaccine
~ Suitability for stockpiling in preparation for H1N1 flu pandemic ~
Lipoxen plc, a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, and Cambridge Biostability Ltd (CBL), the developer of temperature stable vaccines and biopharmaceuticals, are pleased to announce that they have achieved positive preclinical results for the delivery of a novel and enhanced influenza vaccine based on the combination of Lipoxen’s novel vaccine delivery system ‘ImuXen’ and CBL’s proprietary VitRIS stabilisation platform.
Lipoxen, in association with CBL and with funding from the Technology Strategy Board (formerly the DTI), have created a novel water-free influenza vaccine formulation, that will be heat and freeze stable and will not require refrigeration during transport, storage and distribution.
The results of the study give clear indication that Lipoxen’s vaccine technology coupled with CBL’s formulation techniques, not only provide a significantly enhanced vaccine response but also a dramatic advantage in increased vaccine production rates. This advantage addresses the greatest need of seasonal and pandemic influenza vaccines based on newly emerged flu viruses, such as the recent swine flu outbreak.
click here for Press Release (20)
PR019 – April 2009
CBL produces shelf stable pentavalent botulinum vaccine
Cambridge Biostability announces results of third milestone of its collaboration with DynPort Vaccine Company LLC
Cambridge Biostability Ltd (CBL) and DynPort Vaccine Company LLC (DVC), a CSC (NYSE: CSC) company, have successfully produced a thermally stable, rapidly injectable, pentavalent recombinant botulinum vaccine candidate. Preliminary efficacy studies showed that after storage at 55°C for six months, this stabilised vaccine candidate provided protection against lethal challenge with each of five botulinum neurotoxin serotypes. In contrast, a non-stabilised preparation of the vaccine formulation stored under the same conditions for one month lost the capacity to protect.
click here for Press Release (19)
Cambridge Biostability Limited (CBL) is a privately held UK Biotechnology Company based on the Cambridge Science Park. Operational since 2003, CBL has developed unique technologies and expertise for the formulation of a wide range of pharmaceuticals, vaccines and other biological products in thermo-stable, instantly-injectable formats.
CBL’s technology is based around two main platforms - VitRIS and HydRIS - and a number of ancillary technologies. This provides our scientists with the ability to tailor solutions that closely match the needs of our clients.
VitRIS and HydRIS deliver a number of benefits over traditional formulation methods (including those based on freeze-drying) which can be summarised as follows:
• Long term temperature (from below 0ºC to >50º C)
• Physical stability in ready to inject formats
• Applicability to multi-component or binary drugs
• Applicability to products requiring high concentration of active in stable liquids
• Compatibility with vaccine adjuvants e.g. alum
• Temperature stable rapidly dissolving powders
• Applicability to live viruses and other labile products
Cambridge Biostability Limited is a limited company registered in England & Wales with registered number 003630055 and having its registered office at Unit 184, Cambridge Science Park, Milton Road, Cambridge, CB4 0GA, UK.
e. info@biostability.com